The accumulation of Aβ protein is thought to be the initiating event of AD that triggers a series of downstream processes that leads to synaptic damage and neuronal loss. But these drugs act to control the symptoms rather than alter the course of the disease.įor the past 20 years, knowledge of Aβ plaques has been the focus of most Alzheimer’s drug development. To date, only five medical treatments have been approved for AD. The search for a drug to cure AD has been elusive. Several studies indicate that AD is a multifactorial disease resulting from a complex crosstalk between different pathophysiological processes. Degeneration of these cholinergic neurons is found to take place in AD. Studies have demonstrated that cholinergic synaptic loss and amyloid fibril formation are related to Aβ oligomer neurotoxicity, and to interaction between acetylcholine and Aβ peptide. The Cholinergic hypothesis suggests that AD is due to the reduction in the levels of the neurotransmitter acetylcholine which is synthesized by cholinergic neurons. This leads to the accumulation of Aβ peptides (Aβ40 and Aβ42), an increasing ratio of Aβ42/Aβ40, which induces Aβ amyloid fibril formation and tau (a neural protein) pathology induction, and, consequently, leads to neuronal cell death and neurodegeneration.
The Amyloid hypothesis suggests that the degradation of Aβ, derived from the proteolytic cleavage of amyloid precursor protein (APP), decreases with age or pathological conditions. Currently, there are two main hypotheses proposed for the cause. It is now well known that the pathogenesis of Alzheimer’s disease (AD) is associated with the development of amyloid- β (A β) plaques in the brain and neurofibrillary tangles inside the neurons.ĭespite extensive research, the cause of Alzheimer’s disease is not yet clear. The autopsy of the brain revealed to him two distinctive characteristics of the disease: tangled clumps of nerve fibers and patches of disintegrated nerve cell branches.
This chronic neurodegenerative disease got its name from the work of a German psychiatrist, Alois Alzheimer, who conducted an autopsy on his patient who had suffered loss of memory, disorientation, and severe dementia. The word “Alzheimer’s” first appeared in a German psychiatry handbook called “General Psychiatry” on July 15, 1910. The ROSALIND Platform for nCounter AnalysisĪlzheimer’s disease pathology: a short sentence loaded with fear, confusion, and incredulity.AtoMx™ Spatial Informatics Platform Show submenu.CosMx SMI Overview – Single Cell Imaging.CosMx™ Spatial Molecular Imager Show submenu.nCounter Stem Cell Characterization Panel.Stem Cells / Regenerative Medicine Show submenu.GeoMx® Digital Spatial Profiler Show submenu.Elevate your single-cell research with our new spatial multiomics instrument.
0 kommentar(er)
